Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
As of Nov 15, 2026, ANDA 206226 (Entecavir), held by Rising, was first approved by FDA on Mar 26, 2019, with 1 approved supplement and 0 published complete response letters.
First approved: Mar 26, 2019
Review: Standard
Supplements approved: 1
Complete response letters: 0
Approvals and New Uses
The original application and every efficacy supplement, newest first; all 2 submissions below
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters.Drugs@FDA and FDA complete response letters
